What Happened? Hans Biomed Faces Declining Performance and Shareholder Divestment
As of the end of June 2025, Hans Biomed is experiencing a difficult period, with sales decreasing by 18.5% year-on-year and net loss widening. To make matters worse, NP Growth No. 10 Private Equity Fund’s divestment of approximately 6.35% of its stake is adding downward pressure on the stock price.
Why Did This Happen? Poor Performance and Weakened Investor Sentiment
The main cause of the decline in performance is a decrease in exports in the medical device sector. High debt-to-equity ratio and ongoing large-scale lawsuits are also raising concerns about financial soundness. The major shareholder’s divestment is interpreted as a combined result of the private equity fund’s objective to recover its investment and concerns about Hans Biomed’s deteriorating fundamentals.
What’s Next? Short-term Weakness, Mid-to-long-term Uncertainty
A weak stock price is expected in the short term. The release of a large volume of divested shares and negative investor sentiment are likely to pressure the stock price. In the mid-to-long term, the key will be whether the company’s performance improves. The outcome of the lawsuit and the performance of new businesses will be important factors determining the direction of the stock price.
What Should Investors Do? Cautious Approach, Close Monitoring Required
Investors should approach with extreme caution. Rather than hasty investment, it is advisable to carefully observe the company’s fundamental improvement, lawsuit results, new business performance, etc., before making investment decisions. It is recommended to maintain a wait-and-see approach until positive changes appear.
Frequently Asked Questions
What are Hans Biomed’s main businesses?
Hans Biomed’s main products are skin and bone grafts, and medical devices (Mint Lift, hair transplanter, etc.).
Why is the major shareholder’s divestment interpreted as a negative signal?
The major shareholder’s divestment can be interpreted as a sign of lack of confidence in the company’s future value and can act as downward pressure on the stock price.
Should I invest in Hans Biomed?
Currently, Hans Biomed is facing high uncertainty due to poor performance and major shareholder divestment. Investment should be approached with caution, and it’s crucial to carefully examine the company’s future performance and business prospects. This analysis is not investment advice and the responsibility for investment lies with the investor.
